Pretreated Refractory HL
In this video, Dr. Filip Janku, from the University of Texas MD Anderson Cancer Center, discusses the findings of a trial that examined the effect of sirolimus and virinostat in patients with Hodgkin lymphoma who
had been heavily pretreated and had refractory disease. Findings from the study were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting. The combination of the two therapies appeared to be both well tolerated and effective. For more information, click here.